5-(6-(2-chlorophenyl)-2-(methylsulfonyl)pyrimidin-4-yl)-N-isopropylthiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(6-(2-chlorophenyl)-2-(methylsulfonyl)pyrimidin-4-yl)-N-isopropylthiazol-2-amine
• 英文别名: 5-[6-(2-chlorophenyl)-2-methylsulfonylpyrimidin-4-yl]-N-propan-2-yl-1,3-thiazol-2-amine
• 化学式: C₁₇H₁₇ClN₄O₂S₂
• 分子量: 408.933
• InChiKey: XPFBERVLCXQLTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-(6-(2-chlorophenyl)-2-(methylsulfonyl)pyrimidin-4-yl)-N-isopropylthiazol-2-amine 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 4-(2-chlorophenyl)-6-(2-(isopropylamino)thiazol-5-yl)pyrimidin-2-ol
  参考文献：
  名称：

  Phenyl-substituted pyrimidine compounds useful as kinase inhibitors

  摘要：

  具有化学式(I)的化合物及其药学上可接受的盐和溶剂化合物，可用作激酶抑制剂，其中：X1、X2和X3中的两个是N，剩下的一个是—CR1；R1是氢或—CN；N、G、Z、R2、R3、R4、R5和R6在说明书中有描述。还披露了含有化学式(I)化合物的药物组合物，以及治疗与p38激酶活性相关或与LIM激酶活性相关的病症的方法。

  公开号：

  US20060178388A1
• 作为产物：
  描述：

  5-(6-(2-chlorophenyl)-2-(methylthio)pyrimidin-4-yl)-N-isopropylthiazol-2-amine 在 oxone 作用下， 以 甲醇 、 水 为溶剂， 生成 5-(6-(2-chlorophenyl)-2-(methylsulfonyl)pyrimidin-4-yl)-N-isopropylthiazol-2-amine
  参考文献：
  名称：

  Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors

  摘要：

  The design, synthesis, and structure-activity relationships (SAR) of a series of 2-aminothiazol-5-yl-pyrimidines as novel p38α MAP kinase inhibitors are described. These efforts led to the identification of 41 as a potent p38α inhibitor that utilizes a unique nitrogen-sulfur intramolecular nonbonding interaction to stabilize the conformation required for binding to the p38α active site. X-ray crystallographic studies that confirm the proposed binding mode of this class of inhibitors in p38 α and provide evidence for the proposed intramolecular nitrogen-sulfur interaction are discussed.

  DOI：

  10.1016/j.bmcl.2010.07.102

文献信息

• PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Wrobleski Stephen T.

  公开号：US20100029649A1

  公开（公告）日：2010-02-04

  Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X 1 , X 2 , and X 3 are N, and the remaining one of X 1 , X 2 , and X 3 is —CR 1 ; R 1 is hydrogen or —CN; and N, G, Z, R 2 , R 3 , R 4 , R 5 , and R 6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

  具有公式（I）的化合物及其药学上可接受的盐和溶剂化物，可用作激酶抑制剂，其中：X1、X2中的两个为N，X1、X2、X3中剩余的一个为—CR1；R1为氢或—CN；N、G、Z、R2、R3、R4、R5和R6在说明书中有所描述。还披露了含有公式（I）化合物的制药组合物，以及治疗与p38激酶活性和/或LIM激酶活性相关的疾病的方法。
• US7923556B2
  申请人：——

  公开号：US7923556B2

  公开（公告）日：2011-04-12
• [EN] PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSES PYRIMIDINE A SUBSTITUTION PHENYLE UTILISES EN TANT QU'INHIBITEURS DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2006084017A2

  公开（公告）日：2006-08-10

  [EN] Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X₁, X₂, and X₃ are N, and the remaining one of X₁, X₂, and X₃ is -CR₁; R₁ is hydrogen or -CN; and N, G, Z, R₂, R₃, R₄, R₅, and R₆ are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.
  [FR] La présente invention se rapporte à des composés représentés par la formule (I), et à des sels pharmaceutiquement acceptables et des solvates de ceux-ci, qui sont utiles en tant qu'inhibiteurs de kinases. Dans ladite formule : deux éléments parmi X₁, X₂ et X₃ représentent N, et le troisième représente -CR₁ ; R₁ représente hydrogène ou -CN ; et N, G, Z, R₂, R₃, R₄, R₅ et R₆ sont tels que définis dans le descriptif de l'invention. L'invention a également trait à des compositions pharmaceutiques contenant les composés représentés par la formule (I), et à des méthodes permettant de traiter des troubles associés à l'activité de la kinase p38 et/ou des troubles associés à l'activité de la kinase LIM.
• Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
  申请人：Wrobleski T. Stephen

  公开号：US20060178388A1

  公开（公告）日：2006-08-10

  Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X 1 , X 2 , and X 3 are N, and the remaining one of X 1 , X 2 , and X 3 is —CR 1 ; R 1 is hydrogen or —CN; and N, G, Z, R 2 , R 3 , R 4 , R 5 , and R 6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

  具有化学式(I)的化合物及其药学上可接受的盐和溶剂化合物，可用作激酶抑制剂，其中：X1、X2和X3中的两个是N，剩下的一个是—CR1；R1是氢或—CN；N、G、Z、R2、R3、R4、R5和R6在说明书中有描述。还披露了含有化学式(I)化合物的药物组合物，以及治疗与p38激酶活性相关或与LIM激酶活性相关的病症的方法。
• Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors
  作者：Shuqun Lin、Stephen T. Wrobleski、John Hynes、Sidney Pitt、Rosemary Zhang、Yi Fan、Arthur M. Doweyko、Kevin F. Kish、John S. Sack、Mary F. Malley、Susan E. Kiefer、John A. Newitt、Murray McKinnon、James Trzaskos、Joel C. Barrish、John H. Dodd、Gary L. Schieven、Katerina Leftheris

  DOI：10.1016/j.bmcl.2010.07.102

  日期：2010.10

  The design, synthesis, and structure-activity relationships (SAR) of a series of 2-aminothiazol-5-yl-pyrimidines as novel p38α MAP kinase inhibitors are described. These efforts led to the identification of 41 as a potent p38α inhibitor that utilizes a unique nitrogen-sulfur intramolecular nonbonding interaction to stabilize the conformation required for binding to the p38α active site. X-ray crystallographic studies that confirm the proposed binding mode of this class of inhibitors in p38 α and provide evidence for the proposed intramolecular nitrogen-sulfur interaction are discussed.